4basebio PLC, the Cambridge-based synthetic DNA company, completed a Capital raise of approximately £15m in early November 2026 after shareholders approved the necessary resolutions at a general meeting on 6 November. New shares were admitted to trading on 9 and 10 November, and the company has since received several notifications of changes in major shareholdings, filed on 12 and 13 November.
What the company does
4basebio is a biotechnology company that uses synthetic DNA for next-generation therapeutics and vaccines. Its proprietary enzymatic DNA synthesis platform produces GMP-grade synthetic DNA and mRNA. The company supplies DNA constructs for gene therapies, genome editing, mRNA production and DNA vaccines. Amy Walker is chief executive and Richard Bungay is chief financial officer.
Latest developments
The fundraising was announced on 15 October 2026 and comprised a placing, subscriptions and a retail offer. The company said it had conditionally raised gross proceeds of about £15m, with the retail offer adding a small further amount, and new shares were issued at 515p each. Participants in the placing included existing shareholders and institutions such as M&G Investment Management and Elevage Medical Technologies.
The largest shareholder, 2Invest AG, part of the Deutsche Balaton group, subscribed for about £5m in total. Around £1m was paid in cash and about £4m was settled by offsetting part of an existing Shareholder loan. As a result, the principal of the fully drawn €25m Loan from 2Invest falls to around €21.1m, and its Maturity has been extended by two years to 31 October 2030. Because 2Invest is a substantial shareholder, this was treated as a related party transaction under AIM rules.
Directors also took part, investing about £0.3m between them, including Walker, Bungay and non-executive directors Heikki Lanckriet and Hansjörg Plaggemars. Following completion, the company has 19,234,728 ordinary shares in issue. On 9 November it gave notice of an investor presentation.
Financial and Dividend picture
The half-year report published on 28 September 2026 covered the six months to 30 June 2026. Revenue fell to £0.3m from £1.2m, which the company attributed to project delays, and the loss for the period was £8.9m, reflecting strategic investment. Cash stood at £14.1m at the period end, with runway into late 2027 after a €7m loan drawdown, before the new equity. The company said its qualified Business pipeline had risen sixfold to £63m and sales orders had increased 210% to £1.2m. It expects significant revenue growth in the second half of 2026 and into 2027. No dividend was reported.
Sector and index context
4basebio is one of the more highly valued early-stage biotech companies in the FTSE AIM All Share Index, with a share price in the hundreds of pence. Demand for high-quality DNA starting material is linked to the development of gene therapies, genetic medicines and mRNA vaccines, areas where customer funding and project timing can be unpredictable.
Key risks
The company is loss-making and its revenue remains small, so converting the pipeline into orders is critical. Project delays at customers have already affected revenue. Reliance on a major shareholder for loan funding creates concentration risk, and further capital may be needed if commercial progress is slower than planned. Competition from established DNA Manufacturing methods is also a challenge.
What to watch next
Investors will look for evidence of revenue growth in the second half of 2026, conversion of the £63m pipeline into contracts, updates from the investor presentation and the full-year results.






Please wait processing your request...